Boehringer Ingelheim to acquire Labor Dr Merk & Kollegen
Transaction expands Boehringer Ingelheim’s R&D and clinical manufacturing capabilities with a site focused predominantly on…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
immuno-oncology therapies
China has highest PD-1/PD-L1 combination immuno-oncology therapies clinical trials growth:…
Between 2017 and 2019, the number of clinical trials initiated for PD-1/PD-L1 targeted combination therapies increased…
Gilead and Jounce Therapeutics sign exclusive license pact for novel immunotherapy program
Jounce will lead the development of JTX-1811 through IND clearance, and thereafter, Gilead will have the sole right to develop…